1-17 of 17
Nicola J. Curtin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

Aiste McCormick, Peter Donoghue, Michelle Dixon, Richard O’Sullivan, Rachel L. O’Donnell, James Murray, Angelika Kaufmann, Nicola J. Curtin, Richard J. Edmondson
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (16): 3640.
https://doi.org/10.1158/1078-0432.CCR-24-2051
Published: 15 August 2024
View article titled, Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
Open the PDF for Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib in another window
Journal Articles

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

Aiste McCormick, Peter Donoghue, Michelle Dixon, Richard O'Sullivan, Rachel L. O'Donnell, James Murray, Angelika Kaufmann, Nicola J. Curtin, Richard J. Edmondson
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (8): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-16-0564
Published: 13 April 2017
View article titled, Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
Open the PDF for Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib in another window
Includes: Supplementary data
Journal Articles

DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival

Liam Cornell, Joanne M. Munck, Clara Alsinet, Augusto Villanueva, Laura Ogle, Catherine E. Willoughby, Despina Televantou, Huw D. Thomas, Jennifer Jackson, Alastair D. Burt, David Newell, John Rose, Derek M. Manas, Geoffrey I. Shapiro, Nicola J. Curtin, Helen L. Reeves
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 925–933.
https://doi.org/10.1158/1078-0432.CCR-14-0842
Published: 16 February 2015
View article titled, DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Open the PDF for DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival in another window
Includes: Supplementary data
Journal Articles

Abstract A33: Therapeutic potential of sapacitabine in ovarian cancers defective in homologous recombination

Rachel L. O'Donnell, James CC Murray, Adriana GB Buskin, Sheelagh Frame, David G. Blake, Michelle Dixon, Aiste McCormick, Angelika Kaufmann, E Ruth Plummer, Richard J. Edmondson, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): A33.
https://doi.org/10.1158/1078-0432.OVCA13-A33
Published: 13 May 2014
View article titled, Abstract A33: Therapeutic potential of sapacitabine in ovarian cancers defective in homologous recombination
Journal Articles

Abstract PR06: Ovarian cancers harbor defects in nonhomologous end joining resulting in error prone repair and resistance to rucaparib

Aiste McCormick, Michelle Dixon, Rachel ODonnell, Nicola J. Curtin, Richard J. Edmondson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): PR06.
https://doi.org/10.1158/1078-0432.OVCA13-PR06
Published: 13 May 2014
View article titled, Abstract PR06: Ovarian cancers harbor defects in nonhomologous end joining resulting in error prone repair and resistance to rucaparib
Journal Articles

Abstract PR10: Intra- and intertumor heterogeneity in epithelial ovarian cancer: Consequences for biomarker-dependent stratification of therapies

Rachel L. O'Donnell, Laura C. Woodhouse, Aiste McCormick, Angelika Kaufmann, Michelle Dixon, Asima Mukhopadhyay, Nicola J. Curtin, Richard J. Edmondson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): PR10.
https://doi.org/10.1158/1078-0432.OVCA13-PR10
Published: 13 May 2014
View article titled, Abstract PR10: Intra- and intertumor heterogeneity in epithelial ovarian cancer: Consequences for biomarker-dependent stratification of therapies
Journal Articles

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

Asima Mukhopadhyay, Ahmed Elattar, Aiste Cerbinskaite, Sarah J. Wilkinson, Yvette Drew, Suzanne Kyle, Gerrit Los, Zdenek Hostomsky, Richard J. Edmondson, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2344–2351.
https://doi.org/10.1158/1078-0432.CCR-09-2758
Published: 14 April 2010
View article titled, Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Open the PDF for Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?

Majid Ali, Brian A. Telfer, Cian McCrudden, Martin O'Rourke, Huw D. Thomas, Marzieh Kamjoo, Suzanne Kyle, Tracy Robson, Chris Shaw, David G. Hirst, Nicola J. Curtin, Kaye J. Williams
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6106–6112.
https://doi.org/10.1158/1078-0432.CCR-09-0398
Published: 30 September 2009
View article titled, Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation <em>In vivo</em>?
Open the PDF for Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation <em>In vivo</em>? in another window
Includes: Supplementary data
Journal Articles

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Rachel A. Daniel, Agata L. Rozanska, Huw D. Thomas, Evan A. Mulligan, Yvette Drew, Deborah J. Castelbuono, Zdenek Hostomsky, E. Ruth Plummer, Alan V. Boddy, Deborah A. Tweddle, Nicola J. Curtin, Steven C. Clifford
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1241–1249.
https://doi.org/10.1158/1078-0432.CCR-08-1095
Published: 19 February 2009
View article titled, Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
Open the PDF for Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks

Lisa M. Smith, Elaine Willmore, Caroline A. Austin, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8449–8457.
https://doi.org/10.1158/1078-0432.CCR-05-1224
Published: 01 December 2005
View article titled, The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks
Open the PDF for The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks in another window
Journal Articles

Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

E. Ruth Plummer, Mark R. Middleton, Christopher Jones, Anna Olsen, Ian Hickson, Peter McHugh, Geoffrey P. Margison, Gail McGown, Mary Thorncroft, Amanda J. Watson, Alan V. Boddy, A. Hilary Calvert, Adrian L. Harris, David R. Newell, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3402–3409.
https://doi.org/10.1158/1078-0432.CCR-04-2353
Published: 02 May 2005
View article titled, Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes <em>O</em><sup>6</sup>-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
Open the PDF for Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes <em>O</em><sup>6</sup>-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1 in another window
Journal Articles

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

Nicola J. Curtin, Lan-Zhen Wang, Anthie Yiakouvaki, Suzanne Kyle, Christine A. Arris, Stacie Canan-Koch, Stephen E. Webber, Barbara W. Durkacz, Hilary A. Calvert, Zdenek Hostomsky, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (3): 881–889.
https://doi.org/10.1158/1078-0432.CCR-1144-3
Published: 10 February 2004
View article titled, Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells
Open the PDF for Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells in another window
Journal Articles

Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies

Christopher R. Calabrese, Michael A. Batey, Huw D. Thomas, Barbara W. Durkacz, Lan-Zhen Wang, Suzanne Kyle, Donald Skalitzky, Janke Li, Catherine Zhang, Theodore Boritzki, Karen Maegley, Alan H. Calvert, Zdenek Hostomsky, David R. Newell, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2711–2718.
Published: 01 July 2003
View article titled, Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: <subtitle>Chemopotentiation and Pharmacological Studies</subtitle>
Open the PDF for Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: <subtitle>Chemopotentiation and Pharmacological Studies</subtitle> in another window
Journal Articles

The Impact of p53 Status on Cellular Sensitivity to Antifolate Drugs

Xiaohong Lu, Julie Errington, Nicola J. Curtin, John Lunec, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 2114–2123.
Published: 01 July 2001
View article titled, The Impact of <em>p53</em> Status on Cellular Sensitivity to Antifolate Drugs
Open the PDF for The Impact of <em>p53</em> Status on Cellular Sensitivity to Antifolate Drugs in another window
Journal Articles

In Vitro and in Vivo Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity

Peter G. Smith, Huw D. Thomas, Hannah C. Barlow, Roger J. Griffin, Bernard T. Golding, A. Hilary Calvert, David R. Newell, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 2105–2113.
Published: 01 July 2001
View article titled, <em>In Vitro</em> and <em>in Vivo</em> Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity
Open the PDF for <em>In Vitro</em> and <em>in Vivo</em> Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity in another window
Journal Articles

Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines

Xiaohong Lu, Julie Errington, Victor J. Chen, Nicola J. Curtin, Alan V. Boddy, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 271–277.
Published: 01 January 2001
View article titled, Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines
Open the PDF for Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines in another window
Journal Articles

Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines

Carol A. Delaney, Lan-Z Wang, Suzanne Kyle, Alex W. White, A. Hilary Calvert, Nicola J. Curtin, Barbara W. Durkacz, Zdenek Hostomsky, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (7): 2860–2867.
Published: 01 July 2000
View article titled, Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines
Open the PDF for Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines in another window